On November 11, 2017, the autumn color of Beijing is strong, and the red leaves of the fragrant hills are attractive. NKY PRECISION MEDICINE and the thousands of thousands of German guests gathered at the foot of xiangshan, the first step in a new open source collaboration with Heidelberg university medical school. Germany Heidelberg university school of medicine, has 600 years of history, contributed a number of Nobel Prize winner, is recognized as the world's top medical office, the world's unique heavy ion and proton therapy center is located in the campus. Is the representative of visiting Germany, Heidelberg university women's hospital dean Christof Sohn, professor and Heidelberg university school of medicine, "a new generation MammaScreen early breast cancer in vitro molecular screening technology group leader Dr Sarah Schott. "MammaScreen a new generation of early breast cancer in vitro molecular screening technology" and the German national cancer research center jointly by the university of Heidelberg project, a multi-year research and development, through the detection of specific molecular markers in peripheral blood women, very early accurate diagnosis of breast cancer, can make up for the existing various types of breast cancer screening technology.As well as further screening for breast cancer, MammaScreen researchers have begun to explore the use of ovarian and pancreatic cancer and have made preliminary results. The NKY invited to Sohn to visit Beijing and Schott, Ph.D., professor, as specially invited guests attended the "second session of Beijing precision medical treatment of breast cancer and translational medicine BBS" and MammaScreen technology do academic report, signed a cooperation intentions. At the scene of the signing ceremony, the new open source also invited to Beijing maternity and child health care hospital director of oncology wing-keung cheung, haidian Ma Xiangjun, vice President of the six domestic well-known experts, with the German experts MammaScreen technology principle and clinical trials in China has made the detailed communication, MammaScreen won the experts unanimously spoke highly of China. NKY vice chairman wang jianqiang and professor Sohn respectively signed the letter of intent for the project. "NKY is our best partner in China. Today is the beginning of great cooperation between us, and it is the beginning of a great friendship," said professor Sohn, who was pleased to sign the contract.wang jian qiang, vice chairman of the board of directors has expressed the group completes the determination and confidence in the project, "our NKY has always attached great importance to technical and scientific research, cooperation with the world's top medical school this time, is both an opportunity and challenge for us, in the next clinical trial and marketing, we must achieve excellence and absorption of Germany advanced technology and experience, at the same time listen to domestic experts valuable guidance, to make a benefit of Chinese women's breast cancer detection product." Signing ceremony held at the foot of xiangshan in the day of the second session of Beijing precision medical treatment of breast cancer and translational medicine BBS ", is an annual event, the national breast cancer field sponsored new open source has two years in a row. Hundreds of experts, including academician jin Ming, have come from all over the country to share an academic feast of breast cancer diagnosis and treatment.Dr Sohn and Dr Schott introduced MammaScreen technology in detail at the conference, laying a solid foundation for the future academic promotion of new open source. NKY PRECISION MEDICINE's cooperation with Heidelberg university medical school will surely achieve fruitful results.

It is red dye leaves, passion NKY! At the beginning of October 9, 2017, NKY Pharmaceuticals organized afive days staff-tourism in Japan, Zhang jiajie and other places of the seriesof tour activities, it kicked off or in at dawn, or in the autumn wind blowinggently, or in the misty rain. The enthusiasm of employees, cheeky gratefulsmile, with the care of leaders and take the bus, take the plane to thedifferent destinations and began to dabble in exotic amorous feelings, tastethe beautiful of motherland. Osaka - Kyoto - Nagoya - Tokyo - Mt Fuji, exotic scenery panoramicview. We appreciate with the rise of a patriotic heart, love; Zhang jiajieForest Park Grand Canyon - glass bridge - Phoenix Town, visit the motherlandvast territory and abundant resources, beautiful scenery, scenery unlimited.Feel the civilization of 5000 years of history of the Chinese nation's deep andwide, broad and deep, the heart ascend is as proud of the fearless andconfident all the children of the Yellow Emperor. This is another journey to cultivate character! This is another signof passion! This is another declaration of energy gathering! By the evening of October 27th, 9 people were divided into 9batches, 337 in Zhangjiajie and all in japan. During the period, everyoneenjoyed the beautiful scenery of the motherland and the precious footprints ofeach employee left in the famous places. Their respective stories were filledwith admiration and longing for the beauty of nature. Leave a deep impressionin the Japanese tour staff of Japan's clean and civilized. Tianjin NKY two subsidiaries (Tianjin NKY international trade,Tianjin YaRez) staff has been in mid September 2017 to complete the tour of theYunnan Li jiang Dali. We firmly believe that through this tour activities, not only onceagain showed as the glory and pride, the number of new employees andfraternity, will further enhance the company staff cohesion and centripetalforce of the company's employees, the company culture and cultivate positiveintentions and innovation, to promote the continuous innovation and developmentNKY gathered, high spirited a progressive, positiveenergy class!

In October 24th, the world pharmaceuticalraw materials exhibition (CPhI Worldwide) was held in Frankfurt, Germany, in2017. NKY medical group (NKY, stock code: 300109) subsidiary Boai NKYPharmaceuticals Limited attend this global pharmaceutical industry event with anew attitude - the large special booth, 11 line up of international marketingteam (including 5 employees from differentcountries overseas ) to participate in this event. Introduce the advanced andperfect products to the customers of the world with the new market strategy. NKY Pharmaceuticals has always attachedgreat importance to product development, continuously optimize the managementlevel and product quality, and strive to improve the level of cleanerproduction and sustainable development, to become international renowned producerand solution provider of medicinal materials and functional polymer. In this exhibition, vice chairman WangJianqiang of NKY medical group leading international sales team discussed anddetailed analysis of market strategy, develop a new strategy for theinternational market, and long-term sustainable development planning route ofNKY pharmaceuticals LTD. NKY PVP products and the OraRez products has attractedwide attention in the exhibition, we also promoted the new pharmaceuticalexcipients products of our partners.This exhibition, the German subsidiary of NKYgroup added a new marketing power and will play a key role in the progress ofEuropean business in the future .

Invited by the NKY medical group, the chief executive of Swedish NeoDynamics , Anna Eriksrud visit Beijing on 18~21th September. NeoDynamics is a medical technology company headquartered in Sweden, which is committed to research and develop tumor diagnosis equipment. NeoDynamics has now developed NeoNavia breast biopsy system, and in June 2016 acquired the European Union CE certification. From July 2016, NKY become the biggest shareholder in the NeoDynamics.This is the first time two sides communication in China after NKY become NeoDynamics shareholder, accompanied by Ms. Eriksrud to China, and on behalf of the NKY is professor?xiao-jun Xu, Xu teaches physiology and pharmacology in Karolinska instituteMs. Eriksrud first introduced the clinical results in Europe of NeoNavia in nearly a year to NKY: Till to September 2017, NeoNavia system has eight hospitals in clinical trials in Europe, biopsy sampling for breast cancer patients, accumulative total of around 100 cases, the success rate of about 95%. In addition, a small number of axillary lymph node biopsy is performed, with a success rate of up to 100%. The European doctors involved in clinical trials have given the NeoNavia system a high rating.Just in three days, Ms. Eriksrud respectively visited Beijing mammary gland disease prevention and control of society, the Chinese people's liberation army 307 hospital and scientific Chinese medicine tumor hospital. And has carried on the exchange communication respectively with Huang Yan team of 307 hospital surgical oncology and director wang team of mammary gland tumor hospital.Two experts understand the working principle of NeoNavia system in detail, compare the difference with the existing biopsy device and published their opinion, the two experts have expressed interest in cooperation for clinical testing in China.At the end of the trip, Ms. Eriksrud has strong confidence in the development prospects of NeoNavia in Chinese market. She believes that the rapid development of China's economy and the importance of early diagnosis and treatment of cancer will have a very positive impact on the market of medical products. NKY has excellent brand influence and market appeal in China, which can help to achieve the NeoDynamics market goal in China, and make a number of high technology of NeoDynamics benefit cancer patients.